TARS Bathi mangsa ngarep Tarsus Pharmaceuticals Inc

Simbol lan logo merek tarsusrx.com (TARS)

Tarsus Pharmaceuticals (TARS) is cementing Inertia's status as the standard of care for ocular infections, creating a steady cash flow. The synthesis process for the drops is AI-automated, although the clinical application requires physician oversight. The primary challenge remains the pace of the flagship product's commercial rollout. The value of 0.02 aligns with the current metric shown in the analytical profit forecast.

TARS: Prakiraan bathi perusahaan Tarsus Pharmaceuticals 26.02.2025 - 17.11.2026

Tarsus Pharma (TARS) - rincian metrik lan laporan keuangan

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:Tarsus Pharmaceuticals Inc, TARS
Produk dadi Tarsus Pharmaceuticals Inc

This indicator reflects the discounted value of expected cash flows, recalculating the business's potential income via the weighted average cost of capital to determine fair value. By analyzing the forward profitability trend, the investor sees the market valuation of Tarsus Pharmaceuticals (TARS), which is supported by the stability of the US domestic market and the absence of geopolitical barriers in the ophthalmology drug sector.